Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 4/20 | 0.43 |
| ▸ | CFD | P00746 | 11/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29545801 | 1.00 | HPGD (0.43) | HPGDCTSCCFDSLC6A2SLC6A4 | |
| SCHEMBL29545357 | 1.00 | HPGD (0.43) | HPGDCTSCCFDSLC6A2SLC6A4 | |
| SCHEMBL17047371 | 1.00 | HPGD (0.43) | HPGDCTSCCFDSLC6A2SLC6A4 | |
| SCHEMBL18578316 | 1.00 | HPGD (0.43) | HPGDCTSCCFDSLC6A2SLC6A4 | |
| SCHEMBL29544919 | 1.00 | HPGD (0.43) | HPGDCTSCCFDSLC6A2SLC6A4 | |
| SCHEMBL20687453 | 1.00 | HPGD (0.43) | HPGDCTSCCFDSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL17023478 | 0.99 | CTSC (0.42) | HPGDCTSCCFDSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL18553939 | 0.99 | CTSC (0.42) | HPGDCTSCCFDSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29545772 | 0.99 | CTSC (0.42) | HPGDCTSCCFDSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29545413 | 0.99 | CTSC (0.42) | HPGDCTSCCFDSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032490-A1 | THERAPEUTIC REGIMENS FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | ACHILLION PHARMACEUTICALS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-12076319-B2 | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-11814363-B2 | Morphic forms of danicopan | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814363-B2 | Morphic forms of danicopan | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | Achillon Pharmaceuticals, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | Achillon Pharmaceuticals, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3340983-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2015130854-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130795-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032490-A1 | THERAPEUTIC REGIMENS FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | CFH, CFD, CFB | HPGD 345/4885CTSC 1458/4885CFD 2/4885 |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | CFD, C9, TFPI | HPGD 2818/4885CTSC 1113/4885CFD 1/4885 |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | HPGD 1561/4885CTSC 500/4885CFD 1/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | HPGD 85/4885CTSC 904/4885CFD 1/4885 |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | CFD, CFH, CFB | HPGD 3464/4885CTSC 398/4885CFD 1/4885 |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, F3 | HPGD 1890/4885CTSC 600/4885CFD 2/4885 |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | HPGD 2340/4885CTSC 1160/4885CFD 1/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | HPGD 380/4885CTSC 473/4885CFD 1/4885 |
| US-12076319-B2 | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria | CFH, CFD, CFB | HPGD 345/4885CTSC 1458/4885CFD 2/4885 |
| US-11814363-B2 | Morphic forms of danicopan | CFD, CFH, C9 | HPGD 2677/4885CTSC 217/4885CFD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.